First-in-man study of ACT-709478, a novel selective triple T-type calcium channel blocker.

Muriel RichardPriska KaufmannRüdiger KornbergerJasper Dingemanse

Published in: Epilepsia (2019)

ACT-709478 exhibits good tolerability and safety after single-dose administration and its pharmacokinetic and pharmacodynamic properties warrant further investigations.

Keyphrases

open label
randomized controlled trial
angiotensin converting enzyme
placebo controlled